Novocure (NVCR) Misses Q2 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
NovoCure Ltd. (NVCR) PT Raised to $44 at Mizuho Securities
July 27, 2018 8:44 AM EDTMizuho Securities raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $44.00 (from $32.00) while maintaining a Buy rating.
Analyst Difei Yang commented, "NovoCure reported 2Q18 results yesterday. Net revenue of $61.5 mil beat FactSet consensus of $59.5 mil while EPS of $(0.17) was slightly below consensus of... More
Deutsche Bank Downgrades NovoCure Ltd. (NVCR) to Hold
July 25, 2018 4:06 PM EDTDeutsche Bank downgraded NovoCure Ltd. (NASDAQ: NVCR) from Buy to Hold with a price target of $31.00.
For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.
Shares of NovoCure Ltd. closed at $36.30 yesterday.
... More